Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

NCT04623242 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04623242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04623242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease
Lead sponsor
Washington University School of Medicine
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2012
Completion date
March 6, 2020
Enrollment
194 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimers disease, alzheimers disease, familial, dementia